ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 220 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $435,000 | -32.2% | 5,169 | -27.4% | 0.00% | -33.3% |
Q3 2021 | $642,000 | -5.4% | 7,118 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $679,000 | -40.4% | 7,118 | -28.8% | 0.00% | -40.0% |
Q1 2021 | $1,139,000 | -56.2% | 10,004 | -46.7% | 0.01% | -54.5% |
Q4 2020 | $2,600,000 | +69.4% | 18,781 | +0.5% | 0.01% | +57.1% |
Q3 2020 | $1,535,000 | +28.1% | 18,680 | +21.9% | 0.01% | +16.7% |
Q2 2020 | $1,198,000 | +106.6% | 15,320 | +17.3% | 0.01% | +50.0% |
Q1 2020 | $580,000 | +134.8% | 13,060 | +126.0% | 0.00% | +300.0% |
Q3 2019 | $247,000 | -32.7% | 5,780 | 0.0% | 0.00% | -50.0% |
Q2 2019 | $367,000 | -67.6% | 5,780 | -64.6% | 0.00% | -66.7% |
Q1 2019 | $1,132,000 | +50.3% | 16,320 | -5.8% | 0.01% | +20.0% |
Q4 2018 | $753,000 | -37.6% | 17,320 | +9.6% | 0.01% | -16.7% |
Q3 2018 | $1,207,000 | +9.3% | 15,805 | +10.0% | 0.01% | 0.0% |
Q2 2018 | $1,104,000 | +46.8% | 14,365 | -2.6% | 0.01% | +50.0% |
Q1 2018 | $752,000 | – | 14,745 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |